References
Adam BL, Qu Y, Davis YW, Ward MD, Clements MA et al (2002) Serum protein fingerprinting
coupled with a pattern-matching distinguishes prostate cancer from benign prostate hyper-
plasia in healthy men. Cancer Res 62:3609–3614
Agnetti G, Kaludercic N, Kane LA, Elliott ST, Guo Y et al (2010) Modulation of mitochondrial
proteome and improved mitochondrial function by biventricular pacing of dyssynchronous
failing hearts. Circulation 3:78–87
Alberts DS, Liu PY, Wilczynski SP, Jang A, Moon J, Ward JH et al (2007) Phase II trial of
imatinib mesylate in recurrent, biomarker positive ovarian cancer (Southwest Oncology Group
Protocol S0211). Int J Gynecol Cancer 17:784–788
Al-Lazikani B, Banerji U, Workman P (2012) Combinatorial drug therapy for cancer in the post-
genomic era. Nat Biotechnol 30:679–691
Anderson NL, Anderson NG (2002) The human plasma proteome. Mol Cell Proteomics 1:
845–867
Asplund A, Edquist P-H, Schwenk JM, Ponten F (2012) Antibodies for profiling of
human proteome – The Human Protein Atlas as a resource for cancer research. Proteomics
12:2067–2077
Barallobre-Barreiro J, Didangelos A, Schoendube FA, Drozdov I, Yin X et al (2012) Proteomics
analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion
injury. Circulation 125:789–802
Birner-Gruenberger R, Schittmayer M, Holzer M, Marsche G (2014) Understanding high-density
lipoprotein function in disease: recent advances in proteomics unravel the complexity of its
composition and biology. Prog Lipid Res 56:36–46
Blennov K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:
605–613
Bluggel M, Spertini F, Lutter P, Wassenberg J, Audran R et al (2011) Toward protein biomarkers
for allergy: CD4þ T cell proteomics in allergic and nonallergic subjects sampled in and out of
pollen season. J Proteome Res 10:1558–1570
Boroveck F, Lovrecic L, Zhou J, Jeong H, Then F et al (2005) Genome-wide expression profiling
of human blood reveals biomarkers for Huntington’s disease. Proc Natl Acad Sci U S A 102:
11023–11028
Boschetti E, Chung MC, Righetti PG (2012) “The quest for biomarkers”: are we on the
right technical track? Proteomics Clin Appl 6:22–41
Breen L, Cao L, Eom K, SrajerGajdosik M, Camara L, Giacometti J et al (2012) High-throughput
fractionation of human plasma for fast enrichment of low- and high-abundance proteins.
Blood Transfus 10:S89–S100
Brinton LT, Brentnall TA, Smith JA, Kelly KA (2012) Metastatic biomarker discovery through
proteomics. Cancer Genomics Proteomics 9:345–356
Cabras T, Pisano E, Mastinu A, Denotti G, Pusceddu PP, Inzitari R, Fanali C, Nemolato S,
Castagnola M, Messana I (2010) Alterations of the salivary secretory peptidome profile in
children affected by type 1 diabetes. Mol Cell Proteomics 9:2099–2108
Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al (2010)
The patterns and dynamic and genomic instability in metastatic pancreatic cancer.
Nature 467:1109–1113
Cao L, Clifton JG, Reutter W, Josic D (2013) Mass spectrometry-based analysis of rat liver and
hepatocellular carcinoma Morris Hepatoma 7777 plasma membrane proteome. Anal Chem
85:8112–8120
Caseiro A, Barros A, Ferreira R, Padr A, Aroso M, Quintaneiro C, Pereira E, Marinheiro R,
Vitorino R, Amado F (2013) Pursuing type 1 diabetes mellitus and related complications
through urinary proteomics. Transl Res 163:188–199
Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB et al (2002a) Proteomic
identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine
The Role of Proteomics in Personalized Medicine 211